Evidence map›Paper›PMID 22232563›Full record

Trial reportMolecular vision2012

Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α.

Xiao-Xia Han, Chang-Mei Guo, Yue Li, Yan-Nian Hui

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC
In one paragraph

Trial report in Molecular vision, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02834663 (Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy), which is not on this map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02834663 phase4completednot on this mapstarted 2016, after this paper: background citation

Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area

TypeinterventionalSponsorWonkwang University HospitalRan2016 to 2019Enrolled25ConditionsNonproliferative Diabetic RetinopathyArmsLucentis
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Celecoxib attenuates retinal angiogenesis in a mouse model of oxygen-induced retinopathy.International journal of clinical and experimental pathology · 2015
    Article
  9. Article
  10. Angiogenic Factors and Cytokines in Diabetic Retinopathy.Journal of clinical & cellular immunology · 2013
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xiao-Xia HanDepartment of Ophthalmology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Chang-Mei Guo
Yue Li
Yan-Nian Hui
Air Force Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAnti-vascular endothelial growth factor (VEGF) agents have recently been used intravitreally during the perioperative period for proliferative diabetic retinopathy (PDR). However, the mechanism of theraputic effects of the agents remains unclear. This study aimed to investigate the effects of intravitreal bevacizumab (IVB) on retinal vascular endothelial cells and expressions of VEGF and hypoxia inducible factor-1α (HIF-1α) in PDR.

methodsTwenty-four patients with PDR were enrolled and randomized to two groups. Twelve eyes of 12 patients of each group received either an intravitreal injection of 1.25 mg bevacizumab or a sham injection 6 days before vitrectomy. Neovascular membranes (NVMs) were collected during pars plana vitrectomy. The numbers of vascular endothelial cells in the NVMs were counted after staining with hematoxylin and eosin and von Willebrand. The expressions of VEGF and HIF-1α in the NVMs were detected through immunohistochemistry. Ten epiretinal membrane specimens from patients with proliferative vitreoretinopathy (PVR) without IVB treatment were set as an additional control.

resultsThe number of vascular endothelial cells in NVMs of the IVB pretreated group was significantly lower than that of the sham group (21.5±3.94 versus 41.33±7.44, p=0.003). The IVB pretreated group also showed significantly lower levels of VEGF and HIF-1α in NVMs than those of the sham group (P(HIF-1α)=0.02, P(VEGF)<0.001). A stepwise regression analysis showed that IVB was a significant negative predictor for the numbers of vascular endothelial cells (β=-0.89, p<0.001) and the expressions of VEGF (β=-0.85, p<0.001) and HIF-1α (β=-0.64, p=0.001) in PDR patients. Epiretinal membranes of the PVR group showed negative staining of VEGF and HIF-1α.

conclusionsPretreatment with IVB in patients with PDR significantly decreased vascular endothelial cells and expressions of VEGF and HIF-1α, which further supports preoperative use of IVB in such patients.

Indexed as

AdultAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabCell CountDiabetic RetinopathyEndothelial CellsFemaleHumansHypoxia-Inducible Factor 1, alpha SubunitImmunohistochemistryMaleMembranesMiddle AgedNeovascularization, PathologicVascular Endothelial Growth Factor AAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID22232563
PMCPMC3253067
OpenAlexW2096195691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.